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Abstract
Renal fibrosis is a common consequence of unilateral ureteral
obstruction, which provides a useful model to investigate the
pathogenesis of obstructive nephropathy and progressive re-
nal fibrosis. Transforming growth factor (TGF-β1) has been
recognized as a key mediator in renal fibrosis by stimulating
matrix-producing fibrogenic cells and promoting extracellular
matrix deposition. Therefore, considerable efforts have been
made to regulate TGF-β signaling for antifibrotic therapy.
Here, we investigated the mode of action of glucosamine
hydrochloride (GS-HCl) on TGF-β1-induced renal fibrosis.
In the obstructed kidneys and TGF-β1-treated renal cells, GS-
HCl significantly decreased renal expression of α-smooth
muscle actin, collagen I, and fibronectin. By investigating
the inhibitory mechanism of GS-HCl on renal fibrosis, we
found that GS-HCl suppressed TGF-β signaling by inhibiting
N -linked glycosylation of the type II TGF-β receptor
(TβRII), leading to an inefficient trafficking of TβRII to the
membrane surface. Defective N -glycosylation of TβRII
further suppressed the TGF-β1-binding to TβRII, thereby
decreasing TGF-β signaling. Notably, GS-HCl treatment sig-
nificantly reduced TGF-β1-induced up-regulation of Smad2/
3 phosphorylation and transcriptional activity in vivo and
in vitro. Taken together, GS-HCl-mediated regulation of
TGF-β signaling exerted an antifibrotic effect, thereby ame-
liorating renal fibrosis. Our study suggests that GS-HCl would
be a promising agent for therapeutic intervention for
preventing TGF-β1-induced renal fibrosis in kidney diseases.
Key message
& Glucosamine-mediated attenuation of TGF-β signaling
ameliorates renal fibrosis in vivo
& TGF-β1-induced fibrogenic action is reduced by glucos-
amine in vitro
& N -glycosylation of the type II TGF-β receptor is
suppressed by glucosamine
& Glucosamine-induced defective N -glycosylation of
TβRII decreases TGF-β signaling.
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Introduction
Glucosamine is a common constituent of glycosaminoglycans
in the cartilage matrix and synovial fluid [1]. It has been
regarded as an anti-arthritis supplement due to its potential
chondro-protective effects in osteoarthritis patients [2]. How-
ever, studies have also demonstrated the protective effect and
anti-inflammatory feature of glucosamine hydrochloride (GS-
HCl) on other diseases, including pulmonary inflammation
and neurological deficits [3, 4].
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Renal fibrosis is a hallmark of chronic kidney disease and
strongly correlates with deterioration of renal function. Under
limited treatment options in the clinical setting, emerging
evidences suggest targeted inhibition of signaling pathways
involved in renal fibrosis as a promising therapeutic strategy
for the treatment of fibrotic kidney diseases [5, 6].
In addition to its diverse regulations in normal physiolog-
ical cellular processes and diseases [7], TGF-β signaling has
been shown to play a critical role as a potent fibrogenic
inducer in renal fibrosis [5, 6]. Evidences have indicated that
TGF-β1 induces renal fibrogenesis by activating interstitial
fibroblasts, myofibroblasts, and tubule epithelial cells [6, 8]
and increasing extracellular matrix proteins [6, 9]. Moreover,
studies have demonstrated the antifibrotic effects after
blocking TGF-β1 activities [10–13].
TGF-β signaling is regulated by posttranslational mod-
ifications [14]. Dysregulation of posttranslational modifi-
cations may contribute to not only aberrant TGF-β sig-
naling, but also TGF-β1-associated diseases. Considering
that the binding of TGF-β1 to the type II TGF-β receptor
(TβRII) is the first step in TGF-β signaling [15], it is
particularly worthy to investigate the TβRII biology. Re-
cently, we have shown that N -glycosylation of TβRII on
its extracellular domain plays a crucial role in its cell
surface transportation and ligand-binding affinity, thereby
affecting downstream signaling [16].
Of note, it has been reported that GS-HCl exerts an inhib-
itory effect on N-glycosylation of certain proteins, including
epidermal growth factor receptor (EGFR) [17] and cyclo-
oxygenase (COX)-2 [18], and modulates their functions by
facilitating protein turnover or reducing phosphorylation.
However, GS-HCl has not been precisely evaluated for its
ability to influence N-glycosylation of TβRII, a protein that
may play a role in TGF-β1-associated diseases by regulating
TGF-β signaling.
In this study, we demonstrated that GS-HCl attenuated
unilateral ureteral obstruction (UUO)-induced renal fibrosis
in vivo and TGF-β1-induced fibrogenic action in vitro. We
also showed that GS-HCl decreased the elevated TGF-β
signaling in renal fibrosis. Further, we presented a mechanism
that GS-HCl inhibited N-glycosylation of TβRII, resulting in
decreased TGF-β signaling by preventing TβRII proteins
from being transported to the cell surface and subsequent
binding with TGF-β1.
Materials and methods
Establishment of UUO model and GS-HCl treatment
Male C57BL/6 mice were obtained from Orient Bio Inc.
(Seongnam, South Korea). Five groups of mice (n =5) were
used for three separate experiments: (1) sham control, (2)
UUO + phosphate-buffered saline (PBS), (3) UUO + GS-
HCl 20 mg/kg, (4) UUO + GS-HCl 40 mg/kg, and (5) UUO
+ GS-HCl 60 mg/kg. UUO was performed as described pre-
viously [19]. GS-HCl (Sigma-Aldrich, St. Louis, MO) was
dissolved in PBS and administered into mice via daily intra-
peritoneal injection with the indicated dose from 7 days prior
to UUO surgery. All mice were sacrificed 14 days after UUO,
and the kidney tissues were collected for various analyses. All
procedures were conducted in accordance with guidelines
provided by the CHA Hospital Animal Care and Use
Committee.
Semiquantitative assessment of renal fibrosis
Kidney sections were prepared at 4-μm thickness and stained
with Masson’s trichrome for light microscopic examination.
Four different randomly selected regions on the stained sec-
tions (three paraffin sections prepared from each kidney) were
analyzed by BX43 Clinical Microscope (Olympus America
Inc., Melville, NY). Fibrosis was graded by two independent
pathologists. According to the Banff quantitative criteria for
interstitial fibrosis [20], the extent of fibrosis in the renal
cortical area up to 5, 6 to 25, 26 to 50, and more than 50%
was graded as score 0, 1, 2, and 3, respectively.
RT-PCR and real-time RT-PCR
Total RNA was extracted using TRIzol Reagent
(Invitrogen, Carlsbad, CA), according to the manufac-
turer ’s instruct ion. PCR was carr ied out using
AccuPowerTM PCR PreMix Kit (Bioneer Co., Daejon,
South Korea) with specific primer pairs. Quantitative
real-time PCR was performed using Power SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA)
on the ViiATM7 Real-time PCR systems (Applied
Biosystems). The mRNA levels of various genes were
measured in triplicate and normalized with 18S. The se-
quences of the primer sets used in this study, including
human/mouse collagen I, fibronectin, α-smooth muscle
actin (α-SMA), E-cadherin, TGF-β1, connective tissue
growth factor (CTGF), GAPDH, and 18S, are available
upon request.
Immunofluorescence assay
HeLa, HKC-8 cells, and tissues were incubated with the
primary antibodies against Flag, protein disulfide isomerase
(PDI), phalloidin, fibronectin, and α-SMA. After incubation
with secondary antibodies, cells and sections were assessed by
the BX43 Clinical (IX51 Inverted) Microscope (Olympus
America Inc.) or confocal laser scanning microscope (LSM-
510; Carl Zeiss, Jena, Germany). Details can be found in
Supplementary methods online.
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Immunohistochemistry assay
Kidney sections were incubated with anti-phospho-Smad3
and anti-fibronectin. The sections were assessed by the
BX43 Clinical Microscope (Olympus America Inc.). Details
can be found in Supplementary methods online.
Cell culture
Human proximal tubular epithelial cells (HKC-8), human
cervical adenocarcinoma cells (HeLa), and mouse primary
renal epithelial cells were maintained in Dulbecco’s modified
Eagle’s medium and Ham’s F12 medium (DMEM/F12;
Invitrogen) and DMEM (WelGENE, Daegu, South Korea).
Details can be found in Supplementary methods online.
Transfection and treatment
HKC-8 and HeLa cells were transfected with FuGENE HD
(Promega, Madison, WI), according to the manufacturer’s
instruction. Cells were treated with D-(+)-glucosamine
hydrochloride and tunicamycin (Sigma-Aldrich). Cells were
then treated with recombinant TGF-β1 (R&D Systems,
Minneapolis, MN) in a serum-free condition. N-glycosyla-
tion was enzymatically removed from the denatured proteins
in the extracts through incubation with PNGase F (New
England Biolabs, Berverly, MA), according to the manufac-
turer’s instruction.
Western blot analysis
Cells and tissues were prepared for immunoblot analysis with
antibodies to Flag, phospho-Smad2, Smad2, phospho-Smad3,
Smad3, fibronectin, α-SMA, and β-actin. Details can be
found in Supplementary methods online.
Luciferase assay
The luciferase activity was analyzed using the Luciferase Assay
System kit (Promega), according to the manufacturer’s proto-
col. Results were done in triplicate and normalized to β-gal
activity. Details can be found in Supplementarymethods online.
Fig. 1 GS-HCl exerts an antifibrotic effect in the UUO-induced renal
fibrosis model. a Different doses of glucosamine hydrochloride were
intraperitoneally injected into mice from 7 days prior to unilateral ureteral
obstruction (UUO) surgery. Kidney sections from various groups 14 days
after UUO were subjected to Masson’s trichrome staining. Semiquantita-
tive assessment of renal fibrosis was performed with scores using a scale
of 0 to 3. Data are the mean ± SEM of four random fields of three paraffin
sections prepared from each kidney (n=5 in each group). *P<0.05 versus
PBS. b Representative photographs of the Masson’s trichrome-stained
sham, UUO, and GS-HCl-administered UUO mouse kidneys. Note that
40 and 60 mg/kg of GS-HCl significantly reduce renal fibrotic lesions
after obstructive injury. Bar=50 μm
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Fig. 2 GS-HCl decreases α-SMA, collagen I, and fibronectin expression
in the mouse model of UUO-induced renal fibrosis. a–f GS-HCl was
daily administered into mice from 7 days prior to UUO. Kidneys were
collected for various analyses 14 days after UUO. a Representative RT-
PCR and b quantitative real-time RT-PCR show that GS-HCl inhibits α-
smooth muscle actin (α-SMA) mRNA expression induced by UUO. *P <
0.05 versus sham control; #P<0.05 versus UUO + PBS. c Immunofluo-
rescence staining for α-SMA shows that GS-HCl reduces expression of
α-SMA protein in the obstructed kidneys. d Representative RT-PCR and
e quantitative real-time RT-PCR show that the elevated mRNA expres-
sion levels of collagen I and fibronectin by UUO are decreased by GS-
HCl administration. ***P <0.0001, **P <0.001 versus sham control;
###P<0.0001, ##P<0.001 versus UUO + PBS. f Immunohistochemical
staining for fibronectin shows that GS-HCl reduces overdeposition of
fibronectin protein in the obstructed kidneys. a , b , d , e Data are the
mean ± SEM of three independent measurements. c–f Representative
photomicrographs of immunostaining were obtained from evaluating
four random fields of each kidney (n =5 in each group). Bar=50 μm
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Flow cytometry
The numbers of biotinylated TGF-β1-bound TβRII mol-
ecules were quantified using biotinylated human TGF-β1
(R&D Systems), according to the manufacturer’s instruc-
tions. Before flow cytometric analysis, cells were treated
with 7-amino-actinmycin D (BD PharMingen, Bedford,
MA) to exclude dead cells. Details can be found in Sup-
plementary methods online.
Statistical analysis
Data obtained from this study are expressed as the mean ±
SEM. Statistical analyses of data were performed by using
SPSS Program forWindows (ver. 17; SPSS Inc., Chicago, IL).
Comparison between groups was made with one-way
ANOVA, followed by the Student–Newman–Keuls test. Sig-
nificance was achieved at P <0.05.
Results
GS-HCl ameliorates renal fibrosis in obstructive nephropathy
We assessed the effect of GS-HCl on renal fibrosis after
injury in vivo. Starting 7 days prior to UUO surgery, we
administered GS-HCl daily into mice via intraperitoneal
injection in dosages of 20, 40, and 60 mg/kg. Semiquantita-
tive determination 14 days after UUO surgery revealed
significantly lower fibrosis score in the obstructed kidneys
treated with GS-HCl (40 and 60 mg/kg) than those treated
with PBS (Fig. 1a). Histological examination showed
Fig. 3 GS-HCl diminishes TGF-β1-induced fibrogenic responses in
renal epithelial cells. a–d HKC-8 cells were treated with 5 mM of GS-
HCl for various time intervals. Cells were then incubated with TGF-β1
(3 ng/ml for 16 h) in a serum-free condition. a , b Representative RT-PCR
and quantitative RT-PCR data show that GS-HCl inhibits TGF-β1-in-
duced collagen I, fibronectin, and α-SMA mRNA expression, while
blocking TGF-β1-mediated suppression of E-cadherin expression. Data
are the mean ± SEM of three independent measurements. ***P<0.0001
versus control without TGF-β1; ###P <0.0001 versus control with
TGF-β1. c Cell lysates were immunoblotted with antibodies to fibronec-
tin, α-SMA, and β-actin. Note that GS-HCl decreases protein expression
of TGF-β1-induced fibronectin and α-SMA. d Immunofluorescence
staining was performed with fibronectin antibody. DAPI, 4′,6-
diamidino-2-phenylindole, was used for nucleus staining (blue). Note
that GS-HCl reduces protein expression of TGF-β1-induced fibronectin.
Bar =50 μm
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obvious interstitial fibrosis, as shown by strong collagen
deposition, in the obstructed kidneys (Fig. 1b). However,
the obstructed kidneys treated with 40 and 60 mg/kg of
GS-HCl displayed minimal interstitial fibrosis. As illustrated
by these results, GS-HCl demonstrates its ability to prevent
UUO-induced renal fibrosis in vivo.
GS-HCl reduces α-SMA expression and ECM induction
in obstructive nephropathy
Activation of α-SMA-positive and matrix-producing
myofibroblasts is a distinctive feature of renal fibrosis
induced by UUO [5, 9]. TGF-β1 stimulates interstitial
fibroblasts and tubular epithelial cells to undergo
myofibroblastic activation, thus rendering them into
matrix-producing fibrogenic cells [5]. To explore whether
GS-HCl regulated α-SMA expression in UUO-induced
renal fibrosis, we examined the expression level of α-
SMA in the sham-operated, UUO-, and GS-HCl-treated
UUO kidneys. The mRNA expression of α-SMA was
barely detectable in the sham-operated kidneys
(Fig. 2a, b). Immunofluorescence staining also showed
positive staining only in the smooth muscle layer of the
blood vessels in the sham-operated kidneys (Fig. 2c). In
contrast, UUO led to the dramatic up-regulation of α-SMA
in the obstructed kidneys. However, α-SMA induction was
markedly reduced by treatment with 40 and 60 mg/kg of
GS-HCl. These data suggest that GS-HCl exhibits potential
to reduce α-SMA-positive myofibroblast activation during
renal fibrosis.
We further investigated whether GS-HCl reduced the
increase of extracellular matrix (ECM) deposition in the
UUO kidney. GS-HCl effectively inhibited mRNA ex-
pression level of major interstitial matrix components,
including fibronectin and collagen I, which were elevated
after obstructive injury (Fig 2d, e). Immunohistochemical
staining produced a similar result of significant decrease
of fibronectin in the GS-HCl-treated UUO kidneys
(Fig. 2f). As demonstrated by these findings, GS-HCl
exerts an inhibitory effect against ECM overproduction
and deposition in the obstructed kidney.
GS-HCl reduces TGF-β1-induced fibrogenic effects in renal
epithelial cells
Next, we studied the inhibitory effect of GS-HCl on TGF-β1-
induced fibrogenic action in renal epithelial cells. TGF-β1
induced mRNA expression of ECM components, including
collagen I and fibronectin, in human kidney tubular epithelial
cells (HKC-8) (Fig. 3a). However, GS-HCl significantly
suppressed TGF-β1-induced collagen I and fibronectin, as
demonstrated by RT-PCR and quantitative real-time RT-PCR
analyses. TGF-β1 also mediated a myofibroblast phenotype
by inducing α-SMA gene expression (Fig. 3b). In addition,
HKC-8 cells demonstrated loss of epithelial characteristics
upon TGF-β1 treatment by decreasing the mRNA expression
of E-cadherin. On the other hand, GS-HCl reduced TGF-β1-
mediatedα-SMA gene induction and blocked the suppression
of E-cadherin expression by TGF-β1. Consistently, GS-HCl
treatment decreased the expression of fibronectin and α-SMA
proteins induced by TGF-β1 (Fig. 3c). Furthermore, immu-
nofluorescence staining revealed an evident reduction of
TGF-β1-induced fibronectin expression after GS-HCl treat-
ment (Fig. 3d). Taken together, these data suggest that GS-
HCl effectively diminishes TGF-β1-mediated fibrogenic ef-
fects in renal epithelial cells.
GS-HCl attenuates TGF-β signaling in vivo and in vitro
In order to explore whether GS-HCl influenced TGF-β
signaling in the obstructed kidney, we next analyzed the
phosphorylation level of Smad3 proteins, which played a
major role in renal fibrosis in the downstream of TGF-β
signaling [15] in an in vivo model of obstructive nephrop-
athy. GS-HCl administration significantly reduced elevated
Smad3 phosphorylation level in the obstructed kidneys
(Fig. 4a, b), implying its ability to attenuate TGF-β sig-
naling in renal fibrosis in vivo. To further address the
physiological significance of GS-HCl on TGF-β signaling
in vitro, we treated GS-HCl in a dose- and time-dependent
manner into the HKC-8 cells and analyzed the phosphory-
lation levels of Smad2 and Smad3 proteins after TGF-β1
stimulation. GS-HCl treatment markedly reduced Smad2/3
Fig. 4 GS-HCl reduces TGF-β signaling in the obstructive mouse
kidneys and renal epithelial cells. a , b Different doses of GS-HCl were
intraperitoneally injected into mice from 7 days prior to UUO surgery.
Fourteen days after UUO, a tissue homogenates were immunoblotted
with phospho-Smad3 and Smad3. Note that elevated Smad3
phosphorylation induced by UUO was significantly decreased by GS-
HCl administration. b Immunohistochemical stainings for phospho-
Smad3 in the kidney sections. Note that GS-HCl reduces the Smad3
phosphorylat ion level elevated by UUO. Representat ive
photomicrographs of immunohistochemical staining were obtained
from analyzing four random fields of each kidney (n=5 in each group).
Bar =50 μm. c , d HKC-8 cells and e mouse primary kidney epithelial
cells were treated with GS-HCl with the indicated doses for the indicated
periods of time. Cells were then incubated with TGF-β1 (5 ng/ml for
30 min) in a serum-free condition. Cell lysates were immunoblotted with
anti-phospho-Smad2/3, anti-Smad2/3, and β-actin. Band intensities
representing pSmad2/3 and Smad2/3 expression levels were converted
by densitometry using ImageJ software into the ratio of pSmad2/3 to
Smad2/3. Note that GS-HCl suppresses phosphorylation of Smad2 and
Smad3. f (CAGA)12-luciferase reporter and β-gal were transfected into
HKC-8 cells. After GS-HCl (24 h) and tunicamycin (TN ; 12 h) treatment,
cells were treated with TGF-β1 at 3 ng/ml for 16 h in a serum-free
condition. Luciferase activity was normalized with β-gal activity. Note
that GS-HCl significantly decreases TGF-β1-induced luciferase activity.
***P<0.0001, **P <0.001 versus control without TGF-β1; ##P<0.001
versus control with TGF-β1
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phosphorylation in a dose- and time-dependent fashion
(Fig. 4c, d). Dramatic decrease of Smad2/3 phosphoryla-
tion upon GS-HCl treatment was also shown in mouse
primary kidney epithelial cells (Fig. 4e). We further
observed that GS-HCl attenuated TGF-β-induced Smad3-
driven CAGA transcriptional activity in a dose-dependent
manner (Fig. 4f). Collectively, these data demonstrate that
GS-HCl effectively attenuates TGF-β signaling.
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GS-HCl inhibits N -glycosylation of TβRII and decreases
TGF-β signaling
Previous reports demonstrated that GS-HCl exerted an inhib-
itory effect on N-glycosylation of certain proteins [17, 18,
21–23]. Furthermore, N -glycosylation level of TβRII was
found to determine TGF-β sensitivity [16]. Therefore, we
hypothesized that GS-HCl reduced TGF-β signaling by
inhibiting N -glycosylation of TβRII. To investigate whether
GS-HCl influencedN-glycosylation of TβRII, we treated GS-
HCl to HKC-8 cells transfected with TβRII. Western blot
analysis on the expression patterns of TβRII showed multi-
bands of high molecular weight over ∼72 kDa (Fig. 5a). To
confirm that the upper bands were produced by N-glycosyla-
tion of TβRII, we introduced tunicamycin, a potent inhibitor
of N-glycosylation which blocks the synthesis of N-glycans,
and PNGase F which eliminates all N -glycans from TβRII.
Only a single band at ∼64 kDawas detected upon tunicamycin
and PNGase F treatment, indicating that the upper bands of
TβRII were associated with N-glycosylation of TβRII. GS-
HCl treatment significantly decreased TβRII expression at
higher molecular weights in a dose-dependent manner. It also
led to the accumulation of TβRII at lower molecular weights
in the range between ∼68 and ∼64 kDa. This result suggested
that most TβRII proteins were impeded by GS-HCl from
being N -glycosylated, while a small portion was still N -
glycosylated. Collectively, these data indicate that GS-HCl
effectively disrupts N-glycosylation of TβRII.
To examine the role of GS-HCl-induced defective N -gly-
cosylation of TβRII in TGF-β signaling, we treated GS-HCl
into HKC-8 cells overexpressing with TβRII and analyzed
Smad2/3 phosphorylation after TGF-β1 stimulation. Indeed,
GS-HCl treatment reduced Smad2/3 phosphorylation in a
dose-dependent fashion. Also, the expression patterns of de-
fectively N -glycosylated TβRII proteins corresponded to the
decrease of Smad2/3 phosphorylation (Fig. 5b). The
Fig. 5 GS-HCl induces defective N-glycosylation of TβRII and reduces
TGF-β signaling. a–c HKC-8 cells were transfected with Flag-tagged
type II TGF-β receptor (TβRII). After 6 h, GS-HCl (indicated doses for
36 h) or tunicamycin (TN; 1 μg/ml for 12 h) was added to the cell
medium. a Cell extracts treated with or without PNGase F were
immunoblotted with antibodies against Flag. Note that GS-HCl effective-
ly inhibits N-glycosylation of TβRII. b After GS-HCl or TN treatment,
cells were incubated with TGF-β1 (5 ng/ml for 30 min) in a serum-free
condition. Cell lysates were immunoblotted with phospho-Smad2/3,
Smad2/3, and Flag. Band intensities representing pSmad2/3 and
Smad2/3 expression levels were converted by densitometry using ImageJ
software into the ratio of pSmad2/3 to Smad2/3. Note that GS-HCl
suppresses phosphorylation of Smad2 and Smad3 as well as N-glycosyl-
ation of TβRII. c (CAGA)12-luciferase reporter and β-gal were co-
transfected with Flag-TβRII into HKC-8 cells. After GS-HCl (24 h)
and TN (12 h) treatment, cells were treated with TGF-β1 at 3 ng/ml for
16 h in a serum-free condition. Luciferase activity was normalized with
β-gal activity. Note that GS-HCl significantly decreases TGF-β1-induced
luciferase activity. ***P <0.0001, * P <0.05 versus control without
TGF-β1; ###P <0.0001 versus control with TGF-β1
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inhibitory effect of GS-HCl on TGF-β signaling was further
demonstrated by decreased TGF-β1-induced transcriptional
activity in a dose-dependent manner (Fig. 5c). Taken together,
these data suggest that GS-HCl inhibits N -glycosylation of
TβRII and subsequently reduces TGF-β signaling.
GS-HCl-induced defectiveN-glycosylation of TβRII controls
cell surface transport of TβRII and TGF-β1-binding to TβRII
N-glycosylation is involved in cell surface transport of mem-
brane proteins, including TGF-β receptors [16, 24]. To inves-
tigate the effect of GS-HCl-induced defectiveN-glycosylation
of TβRII on its cell surface transport, we performed immu-
nofluorescence assay to observe the subcellular localization of
TβRII transiently overexpressed in HeLa cells. TβRII pro-
teins were localized on the membrane surface almost merging
with phalloidin, which stains actin filaments for observing cell
morphology (Fig. 6a). However, many portions of GS-HCl-
treated TβRII were not able to be successfully transported to
the cell surface. Instead, they were predominantly accumulat-
ed in the cytosol merging with PDI, an endoplasmic reticulum
(ER) marker (Fig. 6b). Their localization was comparable to
that of aglycosylated TβRII under the tunicamycin effect.
These findings demonstrate that GS-HCl hinders cell surface
transport of TβRII. Further, the ability of TGF-β1 to bind to
untreated or GS-HCl-treated TβRII was evaluated with
biotinylated TGF-β1 in HKC-8 cells using flow cytometry
(Fig. 6c). The TGF-β1-binding in the PBS-treated cells was
significantly increased in a dose-dependent manner. However,
GS-HCl treatment dramatically reduced the binding of
TGF-β1 to TβRII. This result might be explained by the
inability of GS-HCl-treated TβRII to be successfully
transported to the cell surface. We also observed that GS-
HCl reduced the TGF-β1-binding to TβRII overexpressed
in HKC-8 cells (Supplementary Fig. 1). Therefore, these
findings indicate that GS-HCl impedes N -glycosylation of
TβRII, thereby inhibiting cell surface transport of TβRII
and suppressing subsequent TGF-β1-binding.
Discussion
Renal fibrosis is a common manifestation of chronic kidney
disease. It is widely recognized that TGF-β/Smad signaling
plays an essential role in fibrogenesis. Therefore, regulation of
TGF-β signaling is considered a promising therapeutic option
for the treatment of renal disease [6]. Evidences show that
inhibition of TGF-β signaling by neutralizing TGF-β1 anti-
bodies or soluble TGF-β receptor ameliorates renal fibrosis
in vivo and in vitro [10–13, 25]. Particularly, the administra-
tion of TGF-β receptor kinase inhibitors, such as IN-1130 and
GW788388, has been shown to decrease renal fibrosis by
regulating receptor function [10, 11]. Likewise, regulation of
TβRII could be worthy of examination, since the binding of
TGF-β1 to TβRII is the first critical step in TGF-β signal
transduction.
TGF-β signaling mediates renal fibrosis by stimulating
overproduction of ECM proteins [6, 9] and inducing transfor-
mation of tubular epithelial cells to myofibroblasts through
epithelial–mesenchymal transition [8]. Thus, renal epithelial
cells and kidney tissues undergoing renal fibrosis often exhibit
significantly increased expression of α-SMA and interstitial
matrix components, such as collagen and fibronectin. Our data
showed that GS-HCl effectively inhibited up-regulation of α-
SMA, collagen I, and fibronectin in the TGF-β1-treated renal
epithelial cells (Fig. 3) and mouse UUO kidneys (Fig. 2),
thereby leading to amelioration of renal fibrosis (Fig. 1). Col-
lectively, our in vitro and in vivo data demonstrate the
antifibrotic effect of GS-HCl on renal fibrosis. To investigate
more whether GS-HCl influenced the synthesis of cytokines
mediating renal fibrosis, we particularly measured TGF-β1
and CTGF expression. As a well-known fibrogenic growth
factor, CTGF is induced by TGF-β1, followed by ECM
production [26]. As shown in Supplementary Fig. 2a, UUO
up-regulated TGF-β1 and CTGF mRNA expression. While
mRNA expression of TGF-β1 was not affected, CTGF was
significantly reduced by GS-HCl administration in the ob-
structive kidneys. Western blot analysis also showed that
active dimeric TGF-β1 (25 kDa) was up-regulated by UUO,
but not reduced by GS-HCl (Supplementary Fig. 2b). These
results indicate that GS-HCl may reduce TGF-β1-induced
fibrogenic actions by attenuating TGF-β signaling, rather than
by decreasing TGF-β1 production.
Next, we further addressed that GS-HCl-mediated
antifibrotic effects were associated with GS-HCl-induced at-
tenuation of TGF-β signaling. TβRII is N-glycosylated on its
extracellular domain [27], and we observed that TGF-β sen-
sitivity was determined by different maturation levels of N-
glycosylation of TβRII [16]. And, GS-HCl induced functional
defects of certain proteins, including apoB-100 [21], furin
[22], ICAM-1 [23], EGFR [17], and COX-2 [18], by modu-
lating their N -glycosylation. Through our examination, we
observed that GS-HCl also impeded N -glycosylation of
TβRII (Fig. 5). According to our previous study on the N-
glycosylation of TβRII [16], the upper bands of TβRII (>
∼72 kDa) indicate more processed types of N-glycosylated
TβRII, indicating hybrid or complex types. On the other hand,
the lower bands of TβRII (∼68 kDa) represent the TβRII
undergoing core N -glycosylation to which unprocessed
high-mannose N -glycans are attached. Also, aglycosylated
TβRII under the tunicamycin effect was detected around a
molecular weight of ∼64 kDa. GS-HCl inhibited N -glycosyl-
ation of most TβRII proteins. Yet, TβRII proteins that es-
caped the GS-HCl effect were still N -glycosylated. GS-HCl
further prevented successful trafficking of TβRII to the cell
surface membrane, thus weakening the interaction between
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TβRII and TGF-β1 in signal transduction (Fig. 6). Conse-
quently, GS-HCl reduced Smad2/3 phosphorylation in renal
epithelial cells and UUO kidneys (Figs. 4 and 5). Taken
together, our data demonstrate that GS-HCl-induced inhibi-
tion of TβRII N -glycosylation effectively suppresses TGF-β
signaling.
Fig. 6 GS-HCl-induced inhibition of TβRIIN-glycosylation hinders cell
surface transport of TβRII and subsequent TGF-β1-binding. a , b Immu-
nofluorescence staining shows subcellular localization of TβRII (Flag;
red), a phalloidin (green), and b protein disulfide isomerase (PDI ;
green) in HeLa cells. Phalloidin enabled the observation of cellular
morphology by staining actin filaments. PDI was used as an ER marker.
DAPI , 4′,6-diamidino-2-phenylindole, was used for nucleus staining
(blue). Note that GS-HCl interrupts cell surface transport of TβRII and
leads to the predominant accumulation of TβRII in the cytosol. Bar=
50 μm. c Representative flow cytometric analysis of receptor density for
recombinant human TGF-β1 (rhTGF-β1) at the cell surface. Various
amounts of biotinylated TGF-β1 (0–40 ng) were added to 1×105 HKC-
8 cells treated with or without GS-HCl (5 mM for 36 h). The numbers of
biotinylated TGF-β1-bound TβRII were quantified using rhTGF-β1.
Note that GS-HCl suppresses TGF-β1 binding to TβRII
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N -glycosylation, a form of posttranslational modification
that attaches glycans to proteins or lipids, serves various
functions, including protein stability, proper folding, local-
ization, and ligand–receptor interactions [24, 28, 29]. Par-
ticularly, studies reveal that N -glycosylation plays an im-
portant role in cell surface trafficking of membrane pro-
teins, including CRFR1 [30] and dopamine transporter
[31]. Defective N -glycosylation of these proteins is impli-
cated in intracellular retention, thereby leading to reduced
stimulation potency in response to the ligand. This phe-
nomenon was also reproduced in our previous study show-
ing that defective N -glycosylation, achieved by site-
directed mutagenesis or tunicamycin treatment, attenuated
successful TβRII cell surface transport, leading to de-
creased ligand-binding affinity [16]. The finding in the
present study that GS-HCl is involved in impeding this
function of N -glycosylation is therefore noteworthy in the
regulation of signaling pathway. Furthermore, in addition
to TGF-β1, fibrogenic factors, including EGF, PDGF,
FGF2, CTGF, and AngII, integrate fibrogenic signals and
coordinate ECM production [5]. And, their respective re-
ceptors, such as EGFR [32], FGFR1 [33], β1 intergrin
[34], and AT1a AngII receptor [35], are known to be N -
glycosylated. Therefore, investigating the effect of GS-HCl
on N -glycosylation of these receptors and subsequent sig-
naling pathways will establish the precise mechanism of
GS-HCl on renal fibrosis.
It has been proven that humans tolerate at least
184 mg/kg/day of GS-HCl intake without documented
toxicity or side effects. It is also reported that large doses
of glucosamine supplementation neither cause glucose
intolerance nor affect glucose metabolism [1]. Therefore,
glucosamine supplements possess an advantage in its
application as a therapeutic agent for preventing fibrotic
kidney dysfunction. However, more precise mechanisms
and the therapeutic efficacy against renal fibrosis should
be scrutinized in further studies.
In conclusion, we have herein demonstrated for the first
time that GS-HCl-induced suppression of TGF-β signaling by
inhibiting N -glycosylation of TβRII significantly reduces
renal fibrosis. This was corroborated by the observations that
the expression of key components involved in renal fibrosis
was attenuated by GS-HCl in vitro and in vivo. All together,
these data provide a strong evidence for the clinical efficacy of
glucosamine supplements in the prevention of fibrotic kidney
diseases.
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